Malignant pleural effusions
Aims : To present the recently completed statement of the ERS task force on malignant pleural effusions and the primary results of AMPLE 2 and TAPPS, which are two recent randomised controlled trials on pleural malignancy. An update on the results of recent trials on the oncological management of mesothelioma will also be provided.
Target audience :
Clinical researcher, Thoracic oncologist, Thoracic surgeon, Adult pulmonologist/Clinician
General respiratory patient care
2018 ERS-EACTS statement on malignant pleural effusions
A. Bibby(Bristol (Avon), United Kingdom)
What is the best oncological management strategy for mesothelioma in 2018?
A. Scherpereel(Lille, France)
Talc slurry vs. talc poudrage: primary results of the TAPPS trial
R. Bhatnagar(Bristol, United Kingdom)
Regular vs. symptomatic drainage of indwelling pleural catheters: primary results of the AMPLE 2 trial
G. Lee(Perth (WA), Australia)
. . .